Tech Company Financing Transactions
Koronis Pharmaceuticals Funding Round
Koronis Pharmaceuticals, based in Seattle, received $20 million from Pacific Horizon Ventures and Asset Management Ventures.
Transaction Overview
Company Name
Announced On
6/28/2007
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series D
Investors
Pacific Horizon Ventures (Lead Investor) (Donald Elmer)
Proceeds Purpose
The Series D financing will support Phase 2a proof-of-concept studies
for the Company's lead product candidate, KP-1461, a novel, oral
small-molecule therapeutic that works through Viral Decay Acceleration(TM)
(VDA) for the treatment of human immunodeficiency virus (HIV) infection.
The first of two planned Phase 2a trials is now underway, and the Company
targets completion of the trials in 2008.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
800 5th Ave. 4120
Seattle, WA 98104
USA
Seattle, WA 98104
USA
Phone
Website
Email Address
Overview
Koronis Pharmaceuticals, Inc. is a privately held biotechnology companydeveloping anti-viral therapeutics based on Viral Decay Acceleration(TM).In addition to the Company's lead product candidate, KP-1461 for AIDS/HIV, the Company has programs directed toward the development of therapeutics for hepatitis C and RSV.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Donald Elmer
Chief Executive Officer
Jean-Pierre Laurent
Browse more venture capital transactions:
Prev: 6/27/2007: Intacct venture capital transaction
Next: 6/28/2007: LoyaltyLab venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs